Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer

Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.
Source: Feed4

Leave a Reply

Your email address will not be published. Required fields are marked *